drug-information.ru |
|Follitropin Alfa |
Drugs search, click the first letter of a drug name: | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9 Home Follitropin AlfaPronouncation: (fole-lih-TROE-pin AL-fah)Class: Gonadotropin Trade Names: Trade Names: Mechanism of ActionPharmacologyStimulates ovarian follicular growth in women who do not have primary ovarian failure. PharmacokineticsAbsorptionT max is about 25 hr for an IM dose and about 16 hr for a subcutaneous dose. AUC is about 206 units•hr/L for an IM dose and about 176 units•hr/L for a subcutaneous dose. C max is about 3 units/L and about 9 units/L at steady state. Bioavailability is about 76% for IM dosing and about 66% for subcutaneous dosing. DistributionMean Vd is 10 L. EliminationTotal Cl is 0.6 L/hr for an IV dose. The t ½ is about 50 hr for an IM dose and about 24 hr for a subcutaneous dose. Indications and UsageInduction of ovulation and pregnancy in anovulatory infertile patients in whom the cause of infertility is functional and not caused by primary ovarian failure; to stimulate development of multiple follicles in ovulatory patients undergoing assisted reproductive therapy (ART [eg, in vitro fertilization]); induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not primary testicular failure (except prefilled pen). ContraindicationsWomen and men who exhibit the following: 1) prior hypersensitivity to recombinant FSH preparations or 1 of their excipients; 2) high levels of FSH indicating primary ovarian failure; 3) uncontrolled thyroid or adrenal dysfunction; 4) an organic intracranial lesion such as a pituitary tumor; 5) sex hormone-dependent tumors of the reproductive tract and accessory organs; and in women who exhibit: 6) abnormal uterine bleeding of undetermined origin; 7) ovarian cyst or enlargement of undetermined origin; and 8) pregnancy. Dosage and AdministrationOvulation InductionAdults Subcutaneous Initial dose of first cycle is 75 units/day; an incremental dosage adjustment of up to 37.5 units may be considered after 14 days. Further dose increases of 37.5 units may be made q 7 days if necessary. Treatment duration should not exceed 35 days unless serum estradiol increase indicates imminent follicular development. To complete follicular development and effect ovulation in the absence of an endogenous LH surge, administer 5,000 units human chorionic gonadotropin (hCG) 1 day after last dose of follitropin alfa. Withhold hCG if serum estradiol is over 2,000 pg/mL. In subsequent cycles, individualize initial dose for each patient. Max daily dose is 300 units. Follicle StimulationAdults Subcutaneous 150 units/day started in early follicular phase (cycle day 2 or 3) until sufficient follicular development is attained (in most cases therapy should not exceed 10 days). In patients undergoing ART whose endogenous gonadotropin levels are suppressed, initiate follitropin alfa at a dose of 150 units/day (under 35 yr of age) or 225 units/day (35 yr of age and older). Continue treatment until adequate follicular development is indicated as determined by ultrasound in combination with serum estradiol level measurements. Consider adjusting the dose after 5 days based on patients response; adjust subsequent dosages q 3 to 5 days and by no more than 75 to 150 units additionally at each adjustment (max, 450 units/day). Administer hCG (5,000 to 10,000 units) once adequate follicular development is evident. SpermatogenesisAdults Pretreat with hCG alone (1,000 to 2,250 units 2 to 3 times/wk). Continue hCG for a period sufficient to achieve serum testosterone levels within normal range, which may take 3 to 6 mo. It may be necessary to increase the hCG dose to achieve normal testosterone levels. After normal testosterone levels are reached, follitropin alfa may be administered. Subcutaneous 150 units follitropin alfa 3 times/wk and hCG 1,000 units 3 times/wk. If azoospermia persists, the follitropin alfa dose may be increased to a max of 300 units 3 times/wk. It may be necessary to administer therapy for up to 18 mo to achieve adequate spermatogenesis. General Advice
Storage/StabilityStore unopened single-dose ampules in refrigerator (36° to 46°F) or at controlled room temperature (68° to 77°F). Protect from light. Use immediately after reconstitution. Discard any unused solution. Store unopened multidose vials in refrigerator or at controlled room temperature. Store reconstituted solution in refrigerator or at controlled room temperature. Protect from light and freezing. Discard any unused solution after 28 days. Store prefilled injection pen in refrigerator until dispensed. Upon dispensing, store pen in refrigerator until expiration date, or at controlled room temperature for up to 1 mo or until the expiration date, whichever occurs first. After the first injection, store pen in refrigerator or at controlled room temperature for up to 28 days. Protect from light. Do not freeze. Discard any unused solution after 28 days. Drug InteractionsNone well documented. Laboratory Test InteractionsNone well documented. Adverse ReactionsCardiovascularPalpitation (2%). CNSHeadache (22%); emotional lability (5%); migraine (4%); dizziness (3%); anorexia, anxiety, somnolence, fatigue (2%). DermatologicAcne (4%); injection site pain (3%); pruritus (2%). EENTRhinitis (7%); pharyngitis (3%). GINausea (14%); abdominal pain (9%); diarrhea (8%); flatulence (7%); vomiting (3%); dyspepsia, paresthesia, constipation, ulcerative stomatitis (2%). GenitourinaryOvarian cyst (15%); intermenstrual bleeding (9%); ovarian hyperstimulation (7%); female breast pain, vaginal hemorrhage (4%); dysmenorrhea, cervix lesion, genital moniliasis, menstrual disorder (3%); genital pruritus, leukorrhea, UTI, ovarian disorder, micturition frequency (2%). MetabolicWeight increase (4%). RespiratoryUpper respiratory tract infection (12%); sinusitis (5%); coughing, dyspnea (2%). MiscellaneousPain (6%); back pain (5%); influenza-like symptoms, fever (4%); enlarged abdomen, chest pain, tooth disorder, thirst, myalgia, hot flashes, malaise (2%); hemoptysis; pilonidal cyst; lymphadenopathy; spontaneous abortion; ectopic pregnancy; premature labor; postpartum fever. PrecautionsPregnancyCategory X . LactationUndetermined. ChildrenSafety and efficacy not established. Health care provider useFollitropin alfa should be used only by health care providers thoroughly familiar with infertility problems and their management. Multiple birthsIn ovulation induction trials, 12.3% of live births were multiple births; in in vitro fertilization clinical trials, 44% of live births were multiple births. Ovarian enlargementMild to moderate uncomplicated ovarian enlargement may occur in about 20% of women treated and generally regresses without treatment within 2 to 3 wk. Ovarian hyperstimulation syndrome (OHSS)Warning signs include difficulty breathing, severe pelvic pain, nausea, vomiting, rapid weight gain, stomach pain or bloating, diarrhea, and infrequent urination. May progress within 24 hr to several days to become a serious medical event. Treatment must be stopped and patient hospitalized. To reduce risk of overstimulation of the ovary in women, ensure ovarian response to therapy is closely monitored (eg, serum estradiol levels and ultrasonography). Do not administer hCG to patient if serum estradiol level is more than 2,000 pg/mL. If the ovaries are abnormally enlarged or abdominal pain occurs, discontinue follitropin alfa therapy, do not administer hCG, and caution patient to avoid intercourse. Pulmonary and vascular complicationsIntravascular thrombosis and embolism can reduce blood flow to critical organs (eg, pulmonary infarct, cerebral vascular occlusion) or the extremities (may cause loss of limbs). OverdosageSymptomsOHSS, multiple gestations. Patient Information
Where can I get more information about Follitropin Alfa ? We recommend to use www.Drugs.com Typical mistypes for Follitropin Alfa dollitropin alfa, collitropin alfa, vollitropin alfa, gollitropin alfa, tollitropin alfa, rollitropin alfa, fillitropin alfa, fkllitropin alfa, flllitropin alfa, fpllitropin alfa, f0llitropin alfa, f9llitropin alfa, foklitropin alfa, foplitropin alfa, foolitropin alfa, folkitropin alfa, folpitropin alfa, foloitropin alfa, follutropin alfa, folljtropin alfa, follktropin alfa, follotropin alfa, foll9tropin alfa, foll8tropin alfa, follirropin alfa, follifropin alfa, folligropin alfa, folliyropin alfa, folli6ropin alfa, folli5ropin alfa, folliteopin alfa, follitdopin alfa, follitfopin alfa, follittopin alfa, follit5opin alfa, follit4opin alfa, follitripin alfa, follitrkpin alfa, follitrlpin alfa, follitrppin alfa, follitr0pin alfa, follitr9pin alfa, follitrooin alfa, follitrolin alfa, follitro-in alfa, follitro0in alfa, follitropun alfa, follitropjn alfa, follitropkn alfa, follitropon alfa, follitrop9n alfa, follitrop8n alfa, follitropib alfa, follitropim alfa, follitropij alfa, follitropih alfa, follitropin zlfa, follitropin slfa, follitropin wlfa, follitropin qlfa, follitropin akfa, follitropin apfa, follitropin aofa, follitropin alda, follitropin alca, follitropin alva, follitropin alga, follitropin alta, follitropin alra, follitropin alfz, follitropin alfs, follitropin alfw, follitropin alfq, ollitropin alfa, fllitropin alfa, folitropin alfa, folitropin alfa, folltropin alfa, folliropin alfa, follitopin alfa, follitrpin alfa, follitroin alfa, follitropn alfa, follitropi alfa, follitropinalfa, follitropin lfa, follitropin afa, follitropin ala, follitropin alf, ofllitropin alfa, flolitropin alfa, foliltropin alfa, folltiropin alfa, follirtopin alfa, follitorpin alfa, follitrpoin alfa, follitroipn alfa, follitropni alfa, follitropi nalfa, follitropina lfa, follitropin lafa, follitropin afla, follitropin alaf, ffollitropin alfa, foollitropin alfa, folllitropin alfa, folllitropin alfa, folliitropin alfa, follittropin alfa, follitrropin alfa, follitroopin alfa, follitroppin alfa, follitropiin alfa, follitropinn alfa, follitropin alfa, follitropin aalfa, follitropin allfa, follitropin alffa, follitropin alfaa, etc.
|